Newsflash for the Snoozers - Part 26

Monday, 30th January 2017 11:58 - by Moosh

Oxford Pharmascience (OXP)

An update by OXP has woken up the market and it seems it is now keen to hear what is coming up from OXP during 2017. Today’s newsflash is a short one since there is an interview with Marcelo Bravo, the OXP CEO, floating about somewhere on LSE and there is also something available at BRR Media and I’m sure the CEO will tell it better than I can, because let’s face it, that’s his job.

Most importantly is that OXP is phenomenally funded with over £20m cash as given in the 17 January 2017 company update and some of this is due to the backing of OXP by a fund connected to Neil Woodford, the poster boy for the UK investment industry, which took part in the placing at ~10p during the Summer of 2015 so given the latest price of 2.25p to buy at market close on 27 January 2017, there’s a very good chance of being in profit before Woodford’s ~10p placing tranche breaks even!

Add OXP to your watchlist and keep your eyes out for news in the next few months, and take a look at the interview available at LSE to whet your appetite!

The Writer's views are their own, not a representation of London South East's. No advice is inferred or given. If you require financial advice, please seek an Independent Financial Adviser.